Prolia is the brand name of denosumab, a RANK ligand inhibitor used to treat osteoporosis and bone loss in several high-risk populations. It is indicated for postmenopausal osteoporosis, bone loss from hormone-ablation therapy in prostate or breast cancer, osteoporosis in men, and glucocorticoid-induced osteoporosis. The FDA first approved Prolia on June 1, 2010.
Blockbuster drugs worth hundreds of billions face generic competition as patents expire through 2032. Indian drugmakers could capture $3-5 billion of the opportunity, while GSK and Bristol Myers Squibb prepare for revenue losses.
The Senate HELP Committee advanced a bill to streamline biosimilar approvals by relying on analytical tests, potentially cutting development costs and time. The FDA has issued guidance removing comparative efficacy studies and is working to speed post-exclusivity approvals. Combined with administration support and PBM reforms, these moves aim to increase biosimilar competition and reduce drug prices.
Amgen shares have fallen 12.6% in three months despite relatively solid Q1 results, while Novo Nordisk maintains a 54.6% global GLP-1 market share. Both companies face pipeline competition and pricing pressures.
Recent biosimilar and biologic developments included Health Canada approval of denosumab biosimilars, FDA review actions, and new licensing and commercialisation agreements. Other updates covered court, trial and reimbursement agenda decisions.
Biocon has launched denosumab biosimilars Bosaya and Aukelso in the United States following FDA approval with interchangeable designation. The products target osteoporosis and bone metastases, entering a market where denosumab products generated approximately $5 billion in U.S. sales in 2024. The launch represents a strategic expansion of Biocon's biosimilar portfolio amid competitive market conditions.
Amgen shares have climbed 35% over six months, trading near $388, as analysts raise price targets following strong fourth-quarter 2025 results and expanding oncology pipeline programs including IMDELLTRA and LUMAKRAS.
The FDA approved multiple denosumab biosimilars in late 2025 and issued REMS safety updates emphasizing severe hypocalcemia risk in patients with advanced chronic kidney disease, including reported hospitalizations and fatalities.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07062978 |
A Comparative Study to Valuating the Efficacy and Safety of QL1206 and Prolia® |
RECRUITING | PHASE3 |
| NCT06804590 |
A Study on Efficacy, Safety and Immunogenicity of 9MW0311 in Postmenopausal Women With Osteoporosis |
COMPLETED | PHASE3 |
| NCT06588153 |
A Study for the Evaluation of Efficacy and Safety of Prolia® in Participants With Glucocorticoid-induced Osteoporosis in Mainland China |
ACTIVE_NOT_RECRUITING | PHASE4 |
| NCT06504966 |
Study to Compare the Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of MAB-22 Versus Prolia® |
WITHDRAWN | PHASE3 |
| NCT05352516 |
A Study to Evaluate the Efficacy and Safety of HLX14 vs. Denosumab Prolia® in Postmenopausal Women With Osteoporosis at High Risk of Fracture |
COMPLETED | PHASE3 |
| NCT05345691 |
Comparison of Efficacy, Pharmacodynamics, Safety, and Immunogenicity Between Bmab 1000 and Prolia® in Postmenopausal Women With Osteoporosis |
COMPLETED | PHASE3 |
| NCT05323708 |
Comparison of Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Bmab 1000 and Prolia® in Normal Healthy Volunteers: DENARIUS: DENosumab Pharmacokinetic equivAlence tRIal in Healthy volUnteerS |
COMPLETED | PHASE1 |
| NCT05087030 |
Comparative Efficacy and Safety Study of RGB-14-P and Prolia® in Women With Postmenopausal Osteoporosis |
COMPLETED | PHASE3 |
| NCT04798313 |
Comparing of the Pharmacokinetic, Pharmacodynamic, Safety and Immunogenicity of MW031 and Prolia® in Healthy Adults |
COMPLETED | PHASE1 |
| NCT04591275 |
Clinical Efficacy and Safety Comparative Study Between CMAB807 Injection and Prolia® . |
COMPLETED | PHASE3 |
